Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant and adjuvant vemurafenib, cobimetinib, and atezolizumab in high-risk resectable melanoma
2018-004841-17Phase 2Active
- Sponsor
- Fondazione Melanoma
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of atezolizumab, cobimetinib and vemurafenib in melanoma (2 arms), sponsored by Fondazione Melanoma. Primary endpoint: pathological Complete Response Rate (pCR). Started Oct 2020; status: active.
02
Drugs
atezolizumabcobimetinibvemurafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2018-004841-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004841-17.